GTS Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-27,200
Closed -$5.77M – 2930
2024
Q3
$5.77M Buy
27,200
+2,400
+10% +$614K 0.01% 800
2024
Q2
$6.95M Sell
24,800
-15,500
-38% -$3.69M 0.01% 668
2024
Q1
$10.8M Buy
40,300
+7,500
+23% +$1.77M 0.02% 472
2023
Q4
$7.59M Buy
32,800
+14,000
+74% +$2.45M 0.01% 755
2023
Q3
$2.75M Buy
+18,800
New +$3.54M ﹤0.01% 1283

Other funds holding MDGL

GTS Securities's MDGL Position: Q3 2026 in Review

GTS Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 392 shares — an estimated $210K sold.

GTS Securities first reported a position in MDGL in Q3 2023 and held it in 6 quarters. The position peaked at $1.31M in Q3 2024. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • GTS Securities reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • GTS Securities sold 392 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $210K.
  • GTS Securities first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • GTS Securities's Madrigal Pharmaceuticals position peaked at $1.31M in Q3 2024.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.